Polymer Free Sirolimus Eluting Coronary Stent System
Future Beyond Polymers
Polymers (Durable or Biocompatible) are an integral part of Drug Release Matrix in current generation DES as they ensure the Release Kinetics of the active drug, the critical determinant of antirestenotic efficacy. However, the mechanical properties of the Metallic Cage and Aggressive Inflammatory Reactions during polymer erosion are known to cause.
- Persistent Fibrin Deposition
- Delayed Endothelialisation
- Chronic Inflammation
- Persistent Platelet Activation
Current DES Polymers are often associated with Flaking, Webbing and Peeling which leads to impaired action of active drug.
VIVO ISAR is an innovative technology which eliminates the use of Polymer by using Dual Drug Technology: Sirolimus and Probucol
Sirolimus:
It is a well-studied and clinically proven Immunosuppressant. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mammalian target of rapamycin inhibition (mTOR).
Probucol:
It is historically proven to impose anti-restenosis effects through anti-oxidative and direct anti-proliferative effects. Though in VIVO ISAR, it is not used as an Active Pharmaceutical Ingredient.
Probucol here mimics the role of a Polymer thus functioning as a drug carrier. Probucol is used as a Matrix-Builder for the controlled release of Sirolimus. Probucol binds the drug on the stent and its properties of being hydrophobic and anti-oxidative, facilitates a controlled and continuous drug release.
Probucol provides optimal Drug Release:
Technical Specification
VIVO ISAR Technical Specification
Ordering Information
Compliance Chart
